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Other names: HUNK1; MCAP 
Location: 19p13 
Location_base_pair: position 15252262-15209302 on 
the chromosome 19 genomic sequence. 
DNA/RNA 
Description 
The gene consists of 20 exons that span approximately 
43 kb of genomic DNA in the centromere-to-telomere 
orientation. The translation initiation codon and stop 
codon are located to exon 2 and exon 20, respectively. 
Transcription 
Two isoforms of BRD4 have been reported. The 'BRD4 
long isoform' corresponds to the ordinary full length 
transcript while the 'BRD4 short isoform' corresponds 
to an alternative splicing variant lacking exons 12-20. 
The 'BRD4 long variant' encodes a 6.0 kb transcript 




BRD4 belongs to the BET subgroup of the 
bromodomain superfamily and contains 2 
bromodomains and a conserved ET-domain. 
The open reading frame encodes a 1362 amino acid 
protein with a molecular weight of 200 kDa. 
Expression 
Northen blot analysis has shown an ubiquitous normal 




A striking feature of BRD4 is its association with 
euchromatic regions of mitotic chromosomes. By this 
association, the protein exerts its function as regulator 
of cell cycle progression from G2 to M but also in the 
G1 to S transition. It has also been suggested that the 
association of BRD4 to chromatin is important for the 
transmission of a transcriptional memory during cell 
division. 
Implicated in 
Carcinoma with t(15;19)(q14;p13) 
translocation. 
Prognosis 
Carcinoma with t(15;19) translocation is invariably 
fatal with a rapid clinical course when located to the 
midline thoracic, head and neck structures. One tumor, 
displaying the cytogenetic and molecular cytogenetic 
features of carcinoma with t(15;19) translocation, but
located to the iliac bone, has been reported as 
successfully cured. 
Cytogenetics 
t(15;19)(q14;p13) [reported breakpoints: t(15;19)(q11-
15;p13)]. 
Hybrid/Mutated Gene 
The t(15;19)(q14;p13) results in a BRD4-NUT 
chimeric gene where exon 10 of BRD4 is fused to exon 
2 of NUT. 
Abnormal Protein 
The BRD4-NUT fusion protein is composed of the N-
terminal of BRD4 (amino acids 1-720 out of 1372) and 
almost the entire protein sequence of NUT (amino 
acids 6-1127). The N-terminal of BRD4 includes 
bromodomains 1 and 2 and other, less well 
characterized functional domains. 
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Oncogenesis 
It has been suggested that the oncogenic effect of the 
NUT-BRD4 fusion is caused not only by the abnormal 
regulation of NUT by BRD4 promoter elements but 
also by the consequent ectopic expression of NUT in 
non-germinal tissues. 
Breakpoints 
Note: The vast majority of reported 19p breakpoints 
were assigned to band 19p13, the exception being the 
cytogenetic interpretation of a 19q13 breakpoint 
reported once. The reported breakpoints on 
chromosome 15 have varied (15q11-q15). 
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